Bausch Health Launches ENVIVE™ Daily Probiotic Supplement prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Market movers: Stocks seeing action on Wednesday - and why Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
A roundup of some of the North American equities making moves in both directions today
On the rise
BlackBerry Ltd. (BB-T) was higher on Wednesday after announcing Volvo Group has selected its QNX software for its heavy vehicles’ dynamic software platform.
“We are delighted to extend our partnership with the Volvo Group and help bring to market their world-class fleet of commercial vehicles,” said Senior Vice President and Co-Head of BlackBerry Technology Solutions John Wall. “OEMs are constantly looking to deploy the right software foundation for the safe and secure architecture of the whole truck, and with BlackBerry QNX we are able to deliver the components and fun
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device
News provided by
Share this article
New OVD Offers Exceptional Corneal Protection, Visibility During Ophthalmic Surgery
LAVAL, QC, April 7, 2021 /PRNewswire/ Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health ), today announced that the U.S. Food and Drug Administration (FDA) has approved ClearVisc™ dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. The ClearVisc™ dispersive OVD is the latest advancement in Bausch + Lomb s rich pipeline of ophthalmic surgical devices and is representative of our company s ongoing commitment to delivering innovations that fulfill the unmet needs of our customers, said Joe Gordon, U.S. president, Bausch + Lomb. OVDs play a critical role in cataract surgery as well as many other ophthalmic surgeries. ClearVisc™ offers significant advantages that can help surge
Share this article
Share this article
NEW YORK, April 7, 2021 /PRNewswire/ In 2020, 125 million people around the world had psoriasis, compared to 100 million in 2016, as per the National Psoriasis Foundation. On account of the rising number of people suffering from this skin condition, the global
psoriasis drugs market size will likely grow to $53,210.6 million by 2030 from $14,504.0 million in 2020, at a 14.0% CAGR between 2021 and 2030, according to the market research report published by P&S Intelligence.
A wide range of conditions and diseases can result in psoriasis, including strep throat, cold, dry weather, cuts, scrapes, bug bites, severe sunburn, stress, smoking and exposure to second-hand smoke, family history of psoriasis, and heavy alcohol consumption. Another key driver for the psoriasis drugs market is the booming geriatric population, since the disease is most common in the elderly.
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
News provided by
Share this article
Share this article
LAVAL, Quebec, April 7, 2021 /PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) today announced it will reduce debt by $100 million through the redemption of outstanding senior secured notes, using cash generated from operations.
Bausch Health will redeem $100 million aggregate principal amount of its outstanding 7.00% Senior Secured Notes due 2024, CUSIP Nos. 91911K AK8, C94143 AK7 (the Notes ) on May 7, 2021. The Company previously redeemed a total of $200M aggregate principal amount of the Notes in March 2021.